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Abstract
Background: In cardiac surgery with cardiopulmonary bypass (CPB), large amounts of fluids are administered. CPB
priming with crystalloid solution causes marked hemodilution and fluid extravasation. Colloid solutions may reduce
fluid overload because they have a better volume expansion effect than crystalloids. The European Medicines
Agency does not recommend the use of hydroxyethyl starch solutions (HES) due to harmful renal effects. Albumin
solution does not impair blood coagulation but the findings on kidney function are conflicting. On the other hand,
albumin may reduce endothelial glycocalyx destruction and decrease platelet count during CPB. No large
randomized, double-blind, clinical trials have compared albumin solution to crystalloid solution in cardiac surgery.
Methods/design: In this single-center, double-blind, randomized controlled trial comprising 1386 adult cardiac
surgery patients, 4% albumin solution will be compared to Ringer’s acetate solution in CPB priming and volume
replacement up to 3200 mL during surgery and the first 24 h of intensive care unit stay. The primary efficacy
outcome is the number of patients with at least one major adverse event (MAE) during 90 postoperative days (all-
cause death, acute myocardial injury, acute heart failure or low output syndrome, resternotomy, stroke, major
arrhythmia, major bleeding, infection compromising post-procedural rehabilitation, acute kidney injury). Secondary
outcomes are total number of MAEs, incidence of major adverse cardiac events (MACE; cardiac death, acute
myocardial injury, acute heart failure, arrhythmia), amount of each type of blood product transfused (red blood
cells, fresh frozen plasma, platelets), total fluid balance at the end of the intervention period, total measured blood
loss, development of acute kidney injury, days alive without mechanical ventilation in 90 days, days alive outside
intensive care unit at 90 days, days alive at home at 90 days, and 90-day mortality.
Discussion: The findings of this study will provide new evidence regarding efficacy and safety of albumin solution
in adult patients undergoing cardiac surgery with CPB.
Trial registration: EudraCT (clinicaltrialsregister.eu) 2015–002556-27 Registered 11 Nov 2016 and ClinicalTrials.gov
NCT02560519. Registered 25 Sept 2015.
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Background
In cardiac surgery, intravenous fluid resuscitation is cru-
cial to ensure adequate intravascular volume, stroke vol-
ume, and tissue oxygen delivery. At the same time,
prevention of fluid overload is essential. Acute hypervo-
lemia causes endothelial glycocalyx destruction and fluid
shift to the interstitial space, leading to postoperative
complications and increased mortality [1–3]. Hemodilu-
tion increases the use of packed red blood cell (PRBC)
transfusion, which increases morbidity and mortality
after cardiac surgery [4]. In the literature, controversy
exists about the optimal perioperative fluid management
in patients undergoing cardiac surgery.
Fluid management in cardiac surgery differs from fluid
management in other types of major surgery. As a cen-
tral pathophysiological phenomenon of cardiopulmonary
bypass (CPB), the systemic inflammatory response leads
to damage of the endothelial glycocalyx, capillary hyper-
permeability, microcirculatory dysfunction, and reduced
tissue oxygenation [5, 6]. CPB priming with crystalloid
solutions causes marked hemodilution, decreased colloid
osmotic pressure, and increased total body water con-
tent. As a combined consequence of hyperpermeability
and hemodilution, most patients present with fluid over-
load after CPB. In addition, cardioplegia, deliberate
hypothermia, ischemia-reperfusion injury, systemic
heparinization, other coagulation disturbances, micro-
emboli formation, and high doses of vasoactive and ino-
tropic drugs affect fluid status [7, 8]. The complexity of
hemodynamic impairment occurring during and after
cardiac surgery leads to difficulties in assessing the ac-
tual volume status.
No consensus on the optimal fluid therapy in cardiac
surgery exists. Of note, endothelial glycocalyx destruc-
tion may change the dynamics of colloids and crystal-
loids. Crystalloid solutions affect neither renal function
nor blood coagulation more than hemodilution could
explain. Colloid solutions, due to their volume expansion
capacity, maintain intravascular volume better than crys-
talloids. After major surgery, maintenance of adequate
cardiac preload requires almost twice as much volume of
crystalloids as that of colloids [9]. Thus, colloids may be
more suitable for restrictive fluid therapy in cardiac sur-
gery. Hydroxyethyl starch (HES) solutions have previously
been used for volume expansion in cardiac surgery. How-
ever, two large randomized clinical trials (RCT) showed
harmful effects of rapidly degradable HES solutions on
renal function in critically ill patients [10, 11].
In cardiac surgery, albumin solution has been demon-
strated to maintain hemodynamics as well as HES solu-
tions [12, 13] and better than crystalloids [14]. Albumin
solutions do not impair coagulation [15]. Although albu-
min solution is considered safe with regard to kidney
function, the existing data are conflicting [16]. In a
retrospective cohort study using a propensity score
methodology, albumin administration was associated
with a dose-dependent risk of acute kidney injury (AKI)
[17]. In another retrospective cohort study on on-pump
cardiac surgery, the use of 5% albumin solution was as-
sociated with significantly decreased odds of in-hospital
mortality and all-cause 30-day readmission rate com-
pared with administration of crystalloids alone [18]. In a
small randomized trial on on-pump cardiac surgery (76–
81 patients/group), fluid management with albumin re-
sulted in less positive fluid balance compared to HES
and Ringer’s lactate. However, creatinine levels were sig-
nificantly higher in the early postoperative phase in the
albumin group, compared to Ringer’s lactate and HES
groups [19]. On the other hand, in a randomized con-
trolled trial on off-pump coronary artery bypass surgery
(110 patients/group), preoperative correction of hypoal-
buminemia with exogenous albumin protected from
acute kidney injury [20].
Glycocalyx regulates vascular permeability and inflam-
mation and coagulation on the endothelial surface.
Sphingosine-1-phosphate (S1P) in plasma regulates the
synthesis and degradation of glycocalyx [21]. Further-
more, S1P modulates continuity of tight junctions, an-
other factor related to vascular permeability. Serum
albumin is essential for the bioavailability of S1P [22].
Albumin not only triggers the release of S1P from red
blood cells, the main reservoir of S1P in blood, but also
carries it to S1P-receptors on endothelial cells. Activa-
tion of S1P-receptor 1 on endothelial cells inhibits
matrix metalloproteinase 9 and matrix metalloproteinase
13 dependent shedding of syndecan-1 ectodomain, an
important component of glycocalyx [23]. Removal of
plasma proteins from the culture media results in de-
struction of glycocalyx [23]. Conversely, in experimental
heart transplantation, addition of albumin into the stor-
age solution preserves glycocalyx of the coronary circu-
lation [24]. If the CPB circuit is primed only with
crystalloid solution, initiation of CPB will result in
prompt and profound hypoalbuminemia.
No large RCTs comparing albumin solution to crys-
talloid solution in cardiac surgical patients have been
conducted. Herein, we describe the final protocol
(version 5, 3 September, 2018) for a randomized,
parallel-group, double-blind study comparing 4% albu-
min solution to Ringer’s acetate solution in cardiac
surgery with CPB. We hypothesize that CPB priming
and intravascular volume replacement therapy using
4% albumin causes less major adverse events (MAE)
than Ringer’s acetate solution.
The article is written in accordance with the Standard
Protocol Items: Recommendations for Interventional
Trials (SPIRIT) guidelines. The SPIRIT checklist is pro-
vided as Additional file 1.
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Methods/design
Patients
This study will be a double-blind, randomized, controlled
trial in 1386 cardiac surgery patients scheduled for elective
surgery or operated on during the index admission in
Helsinki University Hospital, Helsinki, Finland. The pa-
tients will be allocated 1:1 into the two study groups.
Inclusion criteria
 Aged 18–90 years
 Primary or repeat open heart surgery procedures,
either independently or in combinations
▪ Coronary artery bypass grafting
▪ Aortic valve replacement/repair
▪ Mitral valve replacement/repair
▪ Tricuspid valve replacement/repair
▪ The maze procedure or its modifications
▪ Aortic root or ascending aorta surgery when no
hypothermic circulatory arrest is required
 Scheduled for elective surgery or operated on during
the index admission
Exclusion criteria
 Immediate emergency surgery (i.e., no time for
recruitment)
 Correction of a congenital cardiac defect
 Preoperative infection compromising post-
procedural rehabilitation
 Preoperative heart failure/low output sdr, defined as
preoperative inotropic support, mechanical
assistance of breathing, preoperative extracorporeal
membrane oxygenation (ECMO) support,
preoperative intra-aortic balloon pump, preoperative
mechanical assistance of left ventricle, preoperative
ejection fraction (EF) < 20% (intraoperative trans-
esophageal echocardiography not included), some
other comparable preoperative conditions; the con-
dition has to be ongoing
 End-stage kidney disease (estimated glomerular
filtration rate (GFR) < 20 mL/min, based on serum/
plasma creatinine)
 Hemophilia A, hemophilia B
 Patient refusal of the use of blood products and
derivatives of blood products
 Ticagrelol, prasugrel, or clopidogrel treatment
within 2 days
 Apixaban or rivaroxaban treatment within 2 days or
dabigatran treatment within 3 days
Intervention
The trial will be an intervention in patients undergoing
cardiac surgery with CPB between two study solutions:
albumin solution at a final concentration of 4% and
Ringer’s acetate solution. The trial consists of two
phases. In both phases the same study solution (albumin
or Ringer’s acetate) will be used in a double-blind fash-
ion (Table 1). In the first phase of the trial, the study so-
lution will be used for priming of the CPB circuit. In the
second phase of the trial, during surgery and during the
first 24 h in the intensive care unit (ICU), study solution
will be used as volume replacement therapy up to 3200
mL. If more than 3200mL of volume replacement is
needed during the second study phase, Ringer’s acetate
solution will be used thereafter. The volume replacement
therapy will not be set by protocol and will be based on
the clinical decision.
Albumin group
 The first phase: The CPB circuit will be initially
primed with 1200 mL of Ringer’s acetate solution in
an unblinded manner. Thereafter, in a blinded
manner, 300 mL of 20% (200 g/L) albumin solution
(Albuman® 200 g/L, Sanquin Plasma Products BV,
the Netherlands) will be added, resulting in a final
albumin concentration of 4% in the priming fluid.
 The second phase: 4% (40 g/L) albumin solution
(Albuman®, Sanquin Plasma Products BV, the
Netherlands) in a blinded manner.
Ringer group
 The first phase: The CPB circuit will be initially
primed with 1200 mL of Ringer’s acetate solution in
an unblinded manner. Thereafter, in a blinded
manner, 300 mL of Ringer’s acetate solution
(RingerAcetat Baxter Viaflo®, Baxter, Finland) will be
added, resulting in pure Ringer’s acetate solution as
the priming fluid.
 The second phase: Ringer’s acetate solution
(RingerAcetat Baxter Viaflo®, Baxter, Finland) in a
blinded manner.
The intervention period will end after the first 24 h of
ICU stay or when the patient leaves the ICU if the latter
occurs within the first postoperative 24 h (Fig. 1.) After
the intervention period, fluids will be administered ac-
cording to local clinical practice.
For physiological basic need of fluid, Ringer’s acetate
solution will be given throughout the intervention period
as a background infusion of 0.5 mL/kg/h, rounded to the
nearest multiple of 10 mL.
Concomitant treatment
Apart from the study intervention, patients will be
treated according to the clinical practice of the hospital.
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Table 1 Trial design for ALBumin In Cardiac Surgery (ALBICS) study
Study intervention Albumin group: study solution Ringer group: study solution
Unblinded CPB priming
Blinded CPB priming
1200mL of Ringer’s acetate
300 mL of 20% albumin
(final albumin concentration of 4%)
1200mL of Ringer’s acetate
300 mL of Ringer’s acetate
(pure Ringer’s acetate)
Blinded volume replacement up to 3200mla Albumin 4% Ringer’s acetate
Unblinded volume replacement over 3200 mla Ringer’s acetate Ringer’s acetate
Other fluid management
Background infusiona Ringer’s acetate 0.5 mL/kg/h Ringer’s acetate 0.5 mL/kg/h
Blood transfusionsa Based on clinical decision, excluding albumin Based on clinical decision, excluding albumin
aDuring surgery and the first 24 h in ICU
Enrolment Allocation Study intervention
Follow-up
90 days
TIMEPOINT
Before 
surgery
Before 
surgery
During
surgery
Before CPB
During first 
24 hours in 
ICU
After 24 hours
of ICU stay
ENROLMENT:
Eligibility screen X
Informed consent X
Randomization X
INTERVENTIONS:
Study solution for 
volume
replacement
X X X
CPB priming with
study solution
X
Research blood 
sampling
X X
ASSESSMENTS:
Baseline data X
Mortality X X X X
Myocardial injury X
Acute heart failure X X X X
Stroke X X
Arrhytmia X X X X
Major bleeding X X X X
Infection X X
Acute kidney injury X X
Total MAE X
MACE X X X X
Transfused blood
products
X
Fluid balance X
Drainage blood loss X
Days alive without 
mecahanical 
ventilation
X
Days alive outside
ICU
X
Days alive at home X
SAE X X X X
Fig. 1 Schedule of procedures. aBlood samples will be collected at the following time points: after placement of the arterial cannula before
induction of anesthesia, 30 min after protamine administration, 6 h after aortic declamping, and 20 ± 1 h after aortic declamping
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This includes transfusion of blood products, except albu-
min. CPB will be performed using a non-pulsatile pump
and a membrane oxygenator in a standard manner. After
protamine administration shed mediastinal blood will be
discarded. According to clinical judgment, the whole
CPB residual volume or part of it may be re-transfused
after weaning from CPB. All drugs (antibiotics, vaso-
active agents, electrolyte concentration, etc.) will be dis-
solved in either 0.9% NaCl or 5% glucose solution
according to the prevailing clinical practice. All drug so-
lutions will be counted in the fluid balance.
Randomization
Randomization will be done every other week at HUS Phar-
macy (the hospital pharmacy of Helsinki University Hospital)
using online software (www.randomization.com) in conjuc-
tion with the production of the blinded study solution bags.
Only the personnel of HUS Pharmacy, who will not take part
in patient care, will be aware of the randomization. Conse-
quently, the entire study group, including the study nurse,
and the personnel taking care of the patients will be kept
blinded to randomization. HUS Pharmacy will deliver a set
of nine study solution bags for each patient (see below). For
each set, HUS Pharmacy will give a unique consecutive allo-
cation number. Randomization of consecutive allocation
numbers into the two study arms will be performed in
blocks before preparation of each lot of study solution bag
sets. One randomized block is equivalent to one produced
lot of study solution bag sets and their respective allocation
numbers. The actual patient randomization will occur pre-
operatively when the next available study solution bag set for
the subsequent study patient will be taken into use (see
below). The allocation number of the study solution bag set
will be the patient’s study number. Varying block sizes will
be used taking into account reductions during public holi-
days. The block sizes will be chosen to match the estimated
patient recruitment rate within the shelf life of the study so-
lution bags (see below). Preferentially, the block sizes will be
24 patients and 30 patients, alternating every other prepar-
ation lot. Other block sizes may be used if needed. In the
blocks, patients will be randomized to the two treatment
groups in a 1:1 ratio, except for the last few blocks of the
study. Patient withdrawal and expiration of study solution
bag sets may imbalance the patient allocation. In order to
compensate for potential imbalance, patients may be ran-
domized unequally in the last few blocks to retain the
intended ratio of 1:1 between the study groups in all study
patients.
Study solutions and blinding
Preparation and disposal of blinded study solution bags
Preparation, packing, and labeling of the blinded study
solution bags will be done in HUS Pharmacy according
to the requirements of Current Good Manufacturing
Practises (cGMP) and the International Council for Har-
monisation Good Clinical Practise (ICH-GCP) guide-
lines. Commercial products Albuman® 200 g/L and
Albuman® 40 g/L are packed in glass bottles and Ringer-
Acetat Baxter Viaflo® in plastic bags. Albumin solution is
slightly viscous and has an easily visible yellow color
while Ringer’s acetate is non-viscous and colorless. To
ensure adequate blinding, both study solutions will be
packed in identical ethyl vinyl acetate (EVA) 500 mL
bags (EVA Parenteral Nutrition Container, Baxter),
which have been tested to be biocompatible for study so-
lutions for at least 28 days and sterile. EVA bags will be
placed in non-transparent cover bags (Opaque Protec-
tion Bag for Light Sensitive Drugs, Maco Pharma,
Germany) labeled with blinded patient-specific labels.
For each patient, HUS Pharmacy will deliver a set of
nine study solution bags: one bag (300 mL) for the first
phase of the trial and eight bags (400 mL/bag) for the
second phase. The shelf life of the study solution bags
will be 28 days, which will leave a 21-day usage time in
addition to a 7-day period reserved for their preparation.
After the intervention period, the personnel of the
Reprocessing Unit for Medical Devices, which does not
take part in patient care, will dispose of both the used
and unused study solution bags.
Blinding during delivery of study solutions
Preoperatively, consecutive study patients will be given
the first available set of blinded study solution bags.
Each set will be labeled with a unique allocation number,
which will also be the patient’s study number. The set
contains nine blinded study solution bags: one bag (300
mL) for the first phase of the trial and eight bags (400
mL/bag) for the second phase (see above). In the first
phase of the trial, the CPB circuit will initially be primed
with 1200mL of Ringer’s acetate solution. To ensure ad-
equate blinding, after systemic heparinization, a small
amount of blood will be drawn from the operation field
to the CPB reservoir to make the initial priming fluid of
Ringer’s acetate blood-colored. For the blinding, the tube
used for filling the CPB reservoir will be covered with
non-transparent adhesive tape to mask the viscosity and
color of the albumin solution. Thereafter, the study solu-
tion bag of 300 mL will be added to the initial priming
fluid. This will result in a total priming volume of 1500
mL containing either albumin solution at a final concen-
tration of 4% (Albumin group) or pure Ringer’s acetate
solution (Ringer group). In the second phase of the trial,
the study solution will be administered using colored
but transparent infusion tubes (B Braun, Infusomat). Be-
cause albumin solution is slightly viscous, which may be
noticed on visual inspection, the drop chamber will be
covered with non-transparent adhesive tape and tubes
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will be prefilled with saline. Study solutions will be ad-
ministered with infusion pumps.
Outcomes
The follow-up period for all primary and secondary out-
come measures will be 90 postoperative days.
Primary outcome measure
The primary efficacy endpoint will be the proportion of
patients with at least one MAE during the study period
of 90 days (Fig. 1). The composite end-point of MAE
was adopted with small modifications from a previous
publication [25].
MAE composition
 All-cause death
 Acute myocardial injury (defined as an increase in
creatinine kinase muscle/brain isoenzymes (CK-MB)
at least ten times as high as the upper normal limit
of the local laboratory, i.e., 70 μg/l)
 New onset of acute heart failure (e.g., pulmonary
edema, cardiogenic shock) or low output syndrome
requiring intravenous inotropic agents and/or intra-
aortic balloon pump support, ECMO support, or
other comparable condition
 Resternotomy, subxiphoidal pericardial drainage, or
other comparable postoperative procedure
 Stroke
 Major arrhythmia (ventricular fibrillation off-CPB,
ventricular tachycardia off-CPB, new onset atrial fib-
rillation of permanent nature requiring anticoagula-
tion, permanent pacing dependency of new onset)
 Major bleeding (chest tube blood loss at 18 h after
surgery over 20 mL/kg) or need of massive red blood
cell transfusion (5 or more units of packed red blood
cells or an equivalent volume of washed red blood
cells within intervention period)
 Infection compromising post-procedural
rehabilitation
 AKI (postoperative creatinine at least two times
compared to the preoperative level), renal
replacement therapy
Secondary outcome measures
 Total number of MAEs (several MAEs per patient to
be counted)
 Incidence of major adverse cardiac event (MACE;
cardiac death, acute myocardial injury, new onset
acute heart failure, arrhythmia)
 Amount of each type of blood products transfused:
a) red blood cell units, b) fresh frozen plasma units,
c) platelet units
 Total fluid balance at the end of the intervention
period
 Total measured blood loss (drainage)
 AKI development
 Days alive without mechanical ventilation in 90 days
 Days alive outside ICU in 90 days
 Days alive at home in 90 days
 90-day mortality
Adverse events and adverse reactions
Adverse events, serious adverse events (SAE), and sus-
pected unexpected serious adverse reactions (SUSAR)
are defined as described in the ICH-GCP. It is, however,
recognized that cardiac surgery itself will result in typical
aberrations in laboratory values, signs, and symptoms.
These will not be classified as adverse events unless they
are considered to be causally related to the study inter-
vention. Events which are considered to be related
directly to typical aberrations of cardiac surgery will not
be classified as adverse events and are listed in
Additional file 2.
Data collection and patient follow-up
All relevant demographic and medical data, including
outcome measures and adverse events, will be collected
in electronic case report forms (CRF). In the operation
theatre and ICU, patients will be monitored continu-
ously according to the clinical routine, and all data will
be extracted from the electronic patient data manage-
ment system (Picis Clinical Solutions, version 8.2.13,
Wakefield, MA, USA) using an information technology
application tailored for the study. On the ward of the
study site (Helsinki University Hospital), the study nurse
will collect laboratory results manually. The study nurse
will review continuous clinical medical notes during the
hospital stay at the time of patient discharge from the
study site (Helsinki University Hospital). The study
nurse will screen all medical notes and laboratory results
of all hospital visits during the 90-day follow-up period
(Fig. 1). After the follow-up period, the patients will be
interviewed per telephone.
Data monitoring
HYKS-institute Ltd will undertake external monitoring of
the validity of the trial conduct and data collection. At least
five first patients will be monitored throughout. Thereafter,
all patients will be monitored for eligibility (inclusion and
exclusion criteria), consent, operation diagnosis, operation
type, and primary outcome measures. In addition, 10% of
the patients in a random manner will be monitored
throughout. In addition to the above-mentioned parame-
ters, this includes the following parameters: comorbidities,
preoperative regular medication, and laboratory values dur-
ing preoperative screening; administered intravenous fluids,
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blood products, and hemostatic drugs as well as diuresis
and bleeding during the intervention period; core labora-
tory values throughout the study period; and adverse events
and serious adverse events throughout the study period.
Sample size analysis
In the literature, the incidence of MACE after cardiac
surgery varies between 11 and 40%. The primary end-
point in the present study, composite MAE, is broader
than MACE and includes the latter. In a previous cohort
study at the study site (Helsinki University Hospital,
Meilahti hospital) the incidence of MAE was 30%. Thus,
this incidence was used in the sample size analysis. Ori-
ginally, it was estimated that 621 patients per group
would be required to detect a 7.5%-unit absolute differ-
ence between the study groups in the primary outcome
measure (proportion of patients with at least one MAE)
with a two-sided significance level α = 0.05, and power
of 80%. Accordingly, the original sample size was 1250
patients.
A predefined confirmatory analysis of incidence of
MAE among the first 550 patients was performed for
potential adaptation of the sample size in order to pre-
serve the 80% power to detect a 7.5%-unit absolute dif-
ference between the study groups. The MAE incidence
after 550 patients was 42%. In empirical analysis (with-
out breaking the allocation code) the assumption of 50%
and 42.5% MAE incidence in the two study groups
turned out to be the “worst case scenario” (i.e., the high-
est needed patient number) with an estimate of 693 pa-
tients required for both patient groups. In accordance
with the new power analysis, the sample size was in-
creased by 2 × (693 − 1250/2) = 136 patients. Hence, the
final adapted sample size will be 1250 + 136 = 1386. The
Data and Safety Monitoring Board (DSMB) approved
the extension of sample size and a decision was made
before the interim analysis of 600 patients. Withdrawn
patients or those who drop out, for whom the primary
endpoint cannot be assessed, will be replaced.
Statistical analyses
The primary efficacy endpoint will be the proportion of
patients with at least one MAE in the study groups dur-
ing the study period of 90 days. Conclusions from this
study will be based on analyses conducted under the
principle of intention-to-treat. For primary outcome,
The Lan-DeMets spending function with O’Brien-Flem-
ing type boundaries will be employed to preserve the
overall two-sided type I error rate at the 0.05 signifi-
cance level. The main conclusions of the study on pri-
mary outcome will be based on Fisher’s exact test
between the treatment groups. The exact boundary
values are p = 0.00132 in the interim analysis and p =
0.04868 in the final analysis.
For the primary outcome variable and for MACE and
AKI incidence of the secondary outcomes, a time-to-
event analysis will also be performed. The timing of
MAEs is classified into four categories: 1) in the operat-
ing theatre, 2) in the intensive care unit, 3) during the
primary stay at the ward of Meilahti hospital, and 4)
after the primary stay at Meilahti hospital during the 90-
day follow-up period.
For secondary outcomes, the proportions are com-
pared with Fisher’s exact text and logistic regression
models. For continuous variables, t-test and linear re-
gression models will be used to evaluate differences be-
tween the treatment groups. All the analyses regarding
the secondary outcomes will be conducted with a two-
sided significance level of 0.05. No correction for the sig-
nificance level will be done due to multiple testing.
Subgroup analyses will be conducted by preoperative
glomerular filtration rate (GFR), EuroScore, and operation
type. For GFR and EuroScore, the patients will be divided
into two groups: those with a value higher and those with
a value lower than the median value. For operation type,
the patients will be divided into those operated on for aor-
tic valve stenosis (including patient with other surgical
corrections in addition to aortic valve stenosis) and those
patients without correction of aortic valve stenosis.
The safety analysis is based on comparison of serious
adverse events (SAE) between the study groups. Due to
its nature, a MAE is always also a SAE. However, a MAE
is not reported as a SAE in order to avoid double report-
ing. Consequently, the final number of SAEs is the sum
of MAEs and the events reported as a SAE. Because a
single patient may have more than one SAE, three differ-
ent statistical analyses will be conducted for evaluation
of study safety:
 The number of patients with at least one SAE using
Fisher’s exact test
 The SAE number per a patient within those study
patients with at least one SAE using t-test
 The SAE number per a patient within all study
patients using t-test
Interim analysis
One interim analysis will be conducted after 600 patients
have been recruited and followed for 90 days. The
principle of intention-to-treatment will be followed in all
group comparisons of the interim analysis. The primary
efficacy analysis (MAE) and safety analysis (MAE + SAE)
will be conducted as described in the “Statistical ana-
lyses” section above.
The Data and Safety Monitoring Board will recom-
mend pausing or stopping the trial if group difference in
the primary outcome measure (proportion with at least
one MAE) is found to be statistically significant at group
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sequential monitoring boundaries using Lan-DeMets
spending functions. The exact boundary value for the in-
terim analysis is p = 0.00132.
Unblinding
The trial will be double-blind. For safety reasons, how-
ever, a premature unblinding of a specific patient may
take place in the following situations:
 The investigator may request unblinding in case of
an immediate safety hazard to the patient. Separate
sealed envelopes for every allocation number will be
available in this case.
 In case of a putative SUSAR, HUS Pharmacy, which
will undertake randomization, will communicate
directly with the Qualified Person Responsible for
Pharmacovigilance of Sanquin Plasma Products B.V.
For interim analysis and after database lock at the end
of the study, HUS-Pharmacy, which will generate the
randomization and does not take part in patient care by
any means, will separate the patients into two blinded
treatment groups (marked by only “group 1” and “group
2”) for statistical analysis. The statistician who performs
the analyses will be blinded for the treatment of these
groups. The final unblinding will occur only after statis-
tical analysis has been fully performed.
Ethics approval, consent to participate, and ethical
considerations
The operative ethics committee of Helsinki University
Hospital approved the study protocol on 6 February
2017 (HUS/2917/2016). In addition, the Finnish Medi-
cines Agency (Fimea, 136/ 2015) has approved the study
protocol. Any modifications to the protocol will be im-
mediately communicated to all responsible authorities.
The trial will be performed according to the current ver-
sion of the Helsinki Declaration (2013).
Eligible patients who undergo cardiac surgery at Mei-
lahti Hospital (Helsinki University Hospital, Helsinki,
Finland) will be recruited to the study. After obtaining
informed consent, elective patients will be recruited dur-
ing the perioperative screening visit for anesthesia. The
patients scheduled for surgery during the index admis-
sion will be recruited as soon as the decision to perform
surgery has been made and informed consent has been
obtained.
Ringer acetate is used as conventional fluid therapy at
the study site. In addition, albumin solutions are used after
clinical consideration perioperatively. In a scientific litera-
ture review during the study design in 2013, a total of 25
RCTs with 1141 patients were found (Additional file 3). In
priming fluid the maximum albumin dose was 80 g and
the highest albumin concentration was 4%. The highest
albumin dose for volume resuscitation was 254 g. The
highest total albumin dose (including priming and volume
resuscitation) was 267 g. No adverse events or transmitted
infections were reported. In the present trial, the albumin
dose in the priming fluid will be 60 g and the concentra-
tion 4%. The highest possible albumin dose for volume re-
suscitation will be 128 g, and thus the highest total
albumin dose will be 188 g. According to the existing lit-
erature, the albumin doses administered in the present
study are considered safe.
Discussion
Optimal fluid therapy in adult cardiac surgery is not
known. Patients receive large amounts of fluids during
surgery, even though avoiding fluid overload and fluid
extravasation may reduce complications [1–3]. Colloid
use in cardiac surgery is preferred, but the data on the
safety of HES solutions remain uncertain [10, 11, 26].
Thus, the assessment of the safety and efficacy of albu-
min solution in cardiac surgery is warranted.
The SAFE study is the only double-blind large scale trial
on albumin use in fluid resuscitation thus far [27]. It com-
pared the effect of albumin to saline on 28-day mortality
in intensive care patients [27]. In terms of the clinical set-
ting, there will be an essential difference between the
SAFE study and the present study. In critically ill patients
of the SAFE study, systemic inflammatory response and
endothelial glycogalyx destruction had already begun be-
fore fluid resuscitation was initiated. This may have led to
extravasation of the study fluid irrespective of its compos-
ition. In cardiac surgery glycogalyx is intact before CPB is
initiated. Albumin in CPB priming prevents CPB-induced
hypoalbuminemia and may reduce endothelial glycogalyx
destruction and, thus, it may maintain microcirculatory
function better [23, 24].
The theoretical basis of the present study is two-fold.
First, by using albumin from the beginning of surgery
and in CPB priming, i.e., before the onset of CPB, we
hypothesize that albumin protects endothelial glycogalyx
from destruction, preserves the microcirculation, and
thus reduces end-organ dysfunction. Albumin may pro-
tect the glycocalyx also by reducing hypervolemia [19].
Second, albumin does not impair blood coagulation [15].
The primary outcome measure of the present study will
be the composite end-point of MAEs, i.e., death, acute
myocardial injury, acute heart failure, resternotomy,
stroke, major arrhythmia, major bleeding, marked infec-
tion, or acute kidney injury. The primary outcome meas-
ure reflects both end-organ dysfunction and bleeding
diathesis.
The present study will explore the effect and the safety of
the 4% albumin in cardiac surgery with CPB compared to
Ringer’s acetate. This study is the first large scale random-
ized, controlled, double-blind trial comparing albumin to
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crystalloid in cardiac surgery. No other such trial was regis-
tered in ClinicalTrials.gov as of July 31, 2019.
Trial status
The first patient was enrolled on 21 March 2017 and the
study is ongoing. At the time of submission the ALBICS
trial has enrolled 1143 patients. The patient recruitment
is expected to be completed in February 2020 and the
follow-up in May 2020. The final protocol version is ver-
sion 5, 3 September, 2018.
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